4-Cbz-piperazine-1-carbonyl Chloride

Catalog No. :
ACEPVX695
CAS No. :
25539-27-9
Molecular Formula :
C13H15ClN2O3
Molecular Weight :
282.73

IUPAC Name:benzyl 4-(chlorocarbonyl)piperazine-1-carboxylate

4-Cbz-piperazine-1-carbonyl Chloride structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg95%$159.00Login to see priceInquiryInquiry
250mg95%$209.00Login to see priceInquiryInquiry
1g95%$270.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name4-Cbz-piperazine-1-carbonyl Chloride
IUPAC Namebenzyl 4-(chlorocarbonyl)piperazine-1-carboxylate
MDL No.MFCD09743772
Molecular FormulaC13H15ClN2O3
Molecular Weight282.73
SMILESO=C(Cl)N1CCN(C(OCC2=CC=CC=C2)=O)CC1
InChI KeyLIOIUTGIECXTGX-UHFFFAOYSA-N
Synonym4-CHLOROCARBONYL-PIPERAZINE-1-CARBOXYLIC ACID BENZYL ESTER;4-Cbz-piperazine-1-carbonyl Chloride;4-CBZ-Piperazine-1-carbonyl;1-Piperazinecarboxylic acid, 4-(chlorocarbonyl)-, phenylmethyl ester;benzyl 4-carbonochloridoylpiperazine-1-carboxylate
CAS No.25539-27-9

Safety Data

Pictogram
Corrosive
Signal Word
Gefahr
Hazard Statement(s)
H290-H314
Precautionary Statement(s)
P234-P260-P264-P280-P301+P330+P331-P303+P361+P353-P304+P340+P310-P305+P351+P338+P310-P363-P390-P405-P406-P501

Synthetic Route by SureRoute

1. ACEPVX695 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACJLZB581 route compound structure diagram
    ACJLZB58131166-44-6 In Stock
  4. Then
  5. ACEPVX695 route product structure diagram
    ACEPVX69525539-27-9
Inquiry

2. ACEPVX695 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACEPVX695 route product structure diagram
    ACEPVX69525539-27-9
Inquiry

Comments (0)